收藏切换
Rapid health technology assessment of ranibizumab for wet age-related macular degeneration
收藏切换
Chao LI, Yi-fang PEI, Ting LI, Tian ZHANG, Ling TAN
Chinese Journal of New Drugs | 2021, 30(13) : 1242 - 1248
Less
收藏切换
Chinese Journal of New Drugs | 2021, 30(13): 1242-1248
Rapid health technology assessment of ranibizumab for wet age-related macular degeneration
Full
Chao LI, Yi-fang PEI, Ting LI, Tian ZHANG, Ling TAN
Affiliations
  • Department of Pharmaceutical Science, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing 100730, China
Published: 2021-07-15
Outline
收藏切换
Objective:

Ranibizumab prevents the formation of new blood vessels and reduces blood vessel permeability via inhibiting vascular endothelia growth factor (VEGF). In clinical, it is mainly used to treat wet age-related macular degeneration (wAMD). In this study, the safety, effectiveness and economics of ranibizumab in the treatment of wAMD were evaluated in order to provide an evidence-based basis for clinical rational use.

Methods:

Databases were systematically searched, including Pubmed, Ovid, the Cochrane Library, CNKI, Wanfang and CMB, according to the inclusion and exclusion criteria. The literatures were screened, the data were extracted, and then qualitative analysis on the results was conducted by 2 researchers separately.

Results:

17 Meta-analyses and 27 pharmacoeconomic studies were included. The results showed that the clinical effectiveness of ranibizumab in the treatment of wAMD was similar to bevacizumab, conbercept and aflibercept. However, compared with the combination of photodynamic therapy (PDT), the single use of ranibizumab had more benefit in improving patients' vision, especially on BCVA. In terms of safety, ranibizumab is safer than bevacizumab. Ranibizumab appeared significantly more cost-effective than the usual treatments, pegaptanib and PDT, while it is not cost-effective compared with bevacizumab, aflibercept and conbercept.

Conclusion:

In the treatment of wAMD, ranibizumab has no significant advantage over other clinically available drugs in effectiveness, but higher safety than bevacizumab, and lower economical than bevacizumab, aflibercept and conbercept.

ranibizumab  /  wet age-related macular degeneration (wAMD)  /  effectiveness  /  safety  /  economic
李超, 裴艺芳, 李婷, 张田, 谭玲. 雷珠单抗治疗湿性年龄相关性黄斑变性的快速卫生技术评估. 中国新药杂志, 2021 , 30 (13) : 1242 -1248 .
Chao LI, Yi-fang PEI, Ting LI, Tian ZHANG, Ling TAN. Rapid health technology assessment of ranibizumab for wet age-related macular degeneration[J]. Chinese Journal of New Drugs, 2021 , 30 (13) : 1242 -1248 .
Year 2021 volume 30 Issue 13
24
6
Cite this Article
BibTeX
Article Info
  • Online Date:2026-10-30
  • Published:2021-07-15
Article Data
Affiliations
History
  • Accepted:2021-01-25
Funding
Affiliations
    Department of Pharmaceutical Science, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing 100730, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT